Literature DB >> 14520597

Influence of iodide and iodolactones on thyroid apoptosis. Evidence that apoptosis induced by iodide is mediated by iodolactones in intact porcine thyroid follicles.

R Langer1, C Burzler, G Bechtner, R Gärtner.   

Abstract

Iodine induced thyroid involution is caused by apoptosis rather than necrosis. This effect of iodide on apoptosis of thyroid epithelial cells may be not a direct one but mediated by iodinated derivatives i.e. of polyunsaturated fatty acids, especially of iodolactones, which have previously shown to inhibit thyroid cell proliferation. We studied the influence on apoptosis of iodide (2 microM and 20 microM) and iodolactone (0.05 microM and 0.5 microM), with and without TSH (1 mU/ml), using a well characterized ex vivo- culture system of intact porcine thyroid follicles in three-dimensional culture. Apoptosis and necrosis was evaluated by electron-microscopy. Stimulation with 2 and 20 microM iodide rapidly induced a rate of apoptosis (4 - 6 %) comparable to about 40-fold lower doses of delta-iodolactone (0.05 microM and 0.5 microM). Addition of TSH (1 mU/ml) caused a slight but not significant further increase of the incidence of apoptotic cells. The rate of necrotic thyroid epithelial cells (1 - 2 %) was similar in all experiments. As delta-iodolactone in very low concentrations--comparable to iodide in higher concentrations--not only inhibits growth but also induces apoptosis, it has to be supposed that the effect of iodide is mediated by this iodinated compound. However, further experiments are necessary to confirm this hypothesis. In addition it could be demonstrated, that apoptosis is a very rapid and limited process in intact follicles. This also may explain, why iodine supplementation even in high doses does not lead to thyroid atrophy but only normalisation of thyroid size. These results confirm that apoptosis is an important regulated and limited mechanism in goiter involution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14520597     DOI: 10.1055/s-2003-42721

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  8 in total

Review 1.  Is iodine a gatekeeper of the integrity of the mammary gland?

Authors:  Carmen Aceves; Brenda Anguiano; Guadalupe Delgado
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-04       Impact factor: 2.673

2.  Thyroid dysfunction in Greece: Results from the national health examination survey EMENO.

Authors:  Paraskevi V Voulgari; Aliki I Venetsanopoulou; Natasa Kalpourtzi; Magda Gavana; Apostolos Vantarakis; Christos Hadjichristodoulou; Grigoris Chlouverakis; Grigoris Trypsianis; Yannis Alamanos; Giota Touloumi
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

3.  Iodine uptake and prostate cancer in the TRAMP mouse model.

Authors:  Paloma Olvera-Caltzontzin; Guadalupe Delgado; Carmen Aceves; Brenda Anguiano
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

4.  Apoptosis of NOD.H2 h4 thyrocytes by low concentrations of iodide is associated with impaired control of oxidative stress.

Authors:  Panayota Kolypetri; George Carayanniotis
Journal:  Thyroid       Date:  2014-05-28       Impact factor: 6.568

5.  Presence of free triiodothyronine and free thyroxine in thyroid follicles may be correlated with the quick secretion of thyroid hormones under certain physiological conditions.

Authors:  Haihong Shi; Wanrong Lin; B O Liang; Huiyao Cai; Qingyan Cai; Yaxiong Shi; Huibin Huang
Journal:  Biomed Rep       Date:  2016-02-10

6.  Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies.

Authors:  Michael B Zimmermann; Valeria Galetti
Journal:  Thyroid Res       Date:  2015-06-18

7.  Prognostic Significance of Sodium Iodide Symporter and Deiodinase Enzymes mRNA Expression in Gastric Cancer.

Authors:  Alok Mishra; Ashutosh Shrivastava
Journal:  Int J Appl Basic Med Res       Date:  2020-01-03

8.  Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).

Authors:  Carmen Aceves; Pablo García-Solís; Omar Arroyo-Helguera; Laura Vega-Riveroll; Guadalupe Delgado; Brenda Anguiano
Journal:  Mol Cancer       Date:  2009-06-06       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.